Dashboard
Poor long term growth as Net Sales has grown by an annual rate of -2.43% and Operating profit at 5.85% over the last 5 years
- INVENTORY TURNOVER RATIO(HY) Lowest at 1.83%
- DEBTORS TURNOVER RATIO(HY) Lowest at 2.43%
- NET SALES(Q) Lowest at CNY 1,173.99 MM
With ROE of 39.69%, it has a very attractive valuation with a 2.83 Price to Book Value
Market Beating performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 24,895 Million (Large Cap)
7.00
NA
2.93%
-0.58
39.69%
2.83
Total Returns (Price + Dividend) 
Tianjin Pharmaceutical Da Ren Tang Group Corp. Ltd. for the last several years.
Risk Adjusted Returns v/s 
News

Tianjin Pharmaceutical Hits Day High with 7.02% Surge in Stock Price
Tianjin Pharmaceutical Da Ren Tang Group Corp. has shown strong stock performance, with notable gains over the past year and year-to-date. The company boasts impressive financial metrics, including a high return on equity and a favorable price-to-book ratio, reflecting its solid market position in the Pharmaceuticals & Biotechnology sector.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot
Shareholding Compare (%holding) 
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is -18.07% vs -14.64% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is 317.24% vs -73.86% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is -11.20% vs -0.36% in Dec 2023
YoY Growth in year ended Dec 2024 is 128.68% vs 10.92% in Dec 2023






